Andrea K Miyahira1, Joshua M Lang2,3, Robert B Den4,5, Isla P Garraway6,7,8, Tamara L Lotan9,10, Ashley E Ross9,10,11, Tanya Stoyanova12, Steve Y Cho2,13, Jonathan W Simons1, Kenneth J Pienta10,11,14, Howard R Soule1. 1. Prostate Cancer Foundation, Santa Monica, California. 2. University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. 3. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 4. Department of Radiation Oncology, Sidney Kimmel Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Cancer Biology, Sidney Kimmel Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 6. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California. 7. Jonsson Comprehensive Cancer Center, Los Angeles,, California. 8. Greater Los Angeles VA Healthcare System, Los Angeles, California. 9. Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland. 10. Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland. 11. Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland. 12. Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California. 13. Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 14. Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: The 2015 Coffey-Holden Prostate Cancer Academy Meeting, themed: "Multidisciplinary Intervention of Early, Lethal Metastatic Prostate Cancer," was held in La Jolla, California from June 25 to 28, 2015. METHODS: The Prostate Cancer Foundation (PCF) sponsors an annual, invitation-only, action-tank-structured meeting on a critical topic concerning lethal prostate cancer. The 2015 meeting was attended by 71 basic, translational, and clinical investigators who discussed the current state of the field, major unmet needs, and ideas for addressing earlier diagnosis and treatment of men with lethal prostate cancer for the purpose of extending lives and making progress toward a cure. RESULTS: The questions addressed at the meeting included: cellular and molecular mechanisms of tumorigenesis, evaluating, and targeting the microenvironment in the primary tumor, advancing biomarkers for clinical integration, new molecular imaging technologies, clinical trials, and clinical trial design in localized high-risk and oligometastatic settings, targeting the primary tumor in advanced disease, and instituting multi-modal care of high risk and oligometastatic patients. DISCUSSION: This article highlights the current status, greatest unmet needs, and anticipated field changes that were discussed at the meeting toward the goal of optimizing earlier interventions to potentiate cures in high-risk and oligometastatic prostate cancer patients.
BACKGROUND: The 2015 Coffey-Holden Prostate Cancer Academy Meeting, themed: "Multidisciplinary Intervention of Early, Lethal Metastatic Prostate Cancer," was held in La Jolla, California from June 25 to 28, 2015. METHODS: The Prostate Cancer Foundation (PCF) sponsors an annual, invitation-only, action-tank-structured meeting on a critical topic concerning lethal prostate cancer. The 2015 meeting was attended by 71 basic, translational, and clinical investigators who discussed the current state of the field, major unmet needs, and ideas for addressing earlier diagnosis and treatment of men with lethal prostate cancer for the purpose of extending lives and making progress toward a cure. RESULTS: The questions addressed at the meeting included: cellular and molecular mechanisms of tumorigenesis, evaluating, and targeting the microenvironment in the primary tumor, advancing biomarkers for clinical integration, new molecular imaging technologies, clinical trials, and clinical trial design in localized high-risk and oligometastatic settings, targeting the primary tumor in advanced disease, and instituting multi-modal care of high risk and oligometastatic patients. DISCUSSION: This article highlights the current status, greatest unmet needs, and anticipated field changes that were discussed at the meeting toward the goal of optimizing earlier interventions to potentiate cures in high-risk and oligometastatic prostate cancerpatients.
Authors: Alison C Tree; Vincent S Khoo; Rosalind A Eeles; Merina Ahmed; David P Dearnaley; Maria A Hawkins; Robert A Huddart; Christopher M Nutting; Peter J Ostler; Nicholas J van As Journal: Lancet Oncol Date: 2013-01 Impact factor: 41.316
Authors: Gustavo E Ayala; Bahar Muezzinoglu; Kai H Hammerich; Anna Frolov; Hao Liu; Peter T Scardino; Rile Li; Mohammad Sayeeduddin; Michael M Ittmann; Dov Kadmon; Brian J Miles; Thomas M Wheeler; David R Rowley Journal: Am J Pathol Date: 2010-12-23 Impact factor: 4.307
Authors: C S Grasso; A K Cani; D H Hovelson; M J Quist; N J Douville; V Yadati; A M Amin; P S Nelson; B L Betz; C-J Liu; K E Knudsen; K A Cooney; F Y Feng; A S McDaniel; S A Tomlins Journal: Ann Oncol Date: 2015-03-03 Impact factor: 32.976
Authors: Joshua J Morigi; Phillip D Stricker; Pim J van Leeuwen; Reuben Tang; Bao Ho; Quoc Nguyen; George Hruby; Gerald Fogarty; Raj Jagavkar; Andrew Kneebone; Adam Hickey; Stefano Fanti; Lisa Tarlinton; Louise Emmett Journal: J Nucl Med Date: 2015-06-25 Impact factor: 10.057
Authors: Scott M Knowles; Richard Tavaré; Kirstin A Zettlitz; Matthew M Rochefort; Felix B Salazar; Ziyue Karen Jiang; Robert E Reiter; Anna M Wu Journal: Clin Cancer Res Date: 2014-10-17 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Elahe A Mostaghel; Stephanie T Page; Daniel W Lin; Ladan Fazli; Ilsa M Coleman; Lawrence D True; Beatrice Knudsen; David L Hess; Colleen C Nelson; Alvin M Matsumoto; William J Bremner; Martin E Gleave; Peter S Nelson Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701
Authors: R Jeffrey Karnes; Voleak Choeurng; Ashley E Ross; Edward M Schaeffer; Eric A Klein; Stephen J Freedland; Nicholas Erho; Kasra Yousefi; Mandeep Takhar; Elai Davicioni; Matthew R Cooperberg; Bruce J Trock Journal: Eur Urol Date: 2017-04-08 Impact factor: 20.096
Authors: Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2019-12-11 Impact factor: 4.104
Authors: Andrea K Miyahira; Jelani C Zarif; Catherine C Coombs; Robert R Flavell; Joshua W Russo; Samir Zaidi; Di Zhao; Shuang G Zhao; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2021-11-03 Impact factor: 4.104
Authors: S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho Journal: Prostate Cancer Prostatic Dis Date: 2016-05-03 Impact factor: 5.554